REal World Data in LYmphoma and Survival in Adults
- Conditions
- Diffuse Large B Lymphoma (DLBCL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)T-cell Lymphoma (T-NHL)Burkitt Lymphoma (BL))Follicular Lymphoma (FL)Hodgkin's Lymphoma (HL)
- Interventions
- Other: Real-life epidemiological platform of lymphoma in France
- Registration Number
- NCT03869619
- Lead Sponsor
- Hospices Civils de Lyon
- Brief Summary
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data.
REALYSA is a platform perfectly set up to
* Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)...
* Document treatment effectiveness in real life and observance
* Address socio-economical questions
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 6000
- Signature of the consent form for participation in the REALYSA cohort
- Aged over 18 at the time of inclusion
- Diagnosed with lymphoma in the last 6 months (180 days)
- Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma
-
Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination)
-
Documented HIV infection
-
Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded:
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- Hairy cell leukemia and variant
- Lymphoplasmacytic lymphoma
- Waldenström macroglobulinemia
- Primary DLBCL of the central nervous system (CNS)
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Mycosis fungoides
- Sézary syndrome
- Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists)
- Post-transplant lymphoproliferative disorders (PTLD)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description All enrolled patients Real-life epidemiological platform of lymphoma in France All patient who signed the consent form for participation to the study
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) 5 years
- Secondary Outcome Measures
Name Time Method Frequency of Second cancers 9 years Frequency of other chronic disease 9 years Net Survival 9 years Response rate 9 years Duration of response 9 years Number of patients included per month in total and according to subtype of lymphoma 5 years Number of patients in each region in total and according to subtype of lymphoma 9 years Progression-Free Survival (PFS) 9 years Event-Free Survival (EFS) 9 years Overall Survival (OS) 9 years Duration of Survival after progression 9 years Time to Next Anti-Lymphoma Treatment (TTNLT) 9 years Frequency of Lymphoma transformations 9 years Number of exposure factors Baseline Number of comorbidities Baseline
Trial Locations
- Locations (37)
METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,
🇫🇷Chambéry, France
Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand
🇫🇷Clermont-Ferrand, France
CHU Francois MITTERRAND
🇫🇷Dijon, France
Service d'Hématologie Clinique, Centre Hospitalier Universitaire Michallon
🇫🇷La Tronche, France
Centre hospitalier Libourne
🇫🇷Libourne, France
Service Oncologie médicale, HOPITAL SAINT VINCENT-DE-PAUL
🇫🇷Lille, France
Service Hématologie Clinique et Thérapie Cellulaire, CHU DE LIMOGES - HOPITAL DUPUYTREN,
🇫🇷Limoges, France
Département d'Hématologie Clinique, Hôpital Saint-Eloi,
🇫🇷Montpellier, France
Service Hématologie, GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER,
🇫🇷Mulhouse, France
Service d'Hématologie clinique, Centre Hospitalier Universitaire de Nantes
🇫🇷Nantes, France
Centre Hospitalier de Niort
🇫🇷Niort, France
Service Hématologie, Hôpital St Louis
🇫🇷Paris, France
CHU Haut-Lévêque
🇫🇷Pessac, France
Hématologie Clinique, CHU PONTCHAILLOU
🇫🇷Rennes, France
Hématologie Clinique, CH DE BRETAGNE ATLANTIQUE
🇫🇷Vannes, France
Institut Bergonié
🇫🇷Bordeaux, France
Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor
🇫🇷Créteil, France
Service Oncologie médicale, Groupe Hospitalier Mutualiste de Grenoble, Institut Daniel Hollard,
🇫🇷Grenoble, France
Clinique Victor Hugo
🇫🇷Le Mans, France
Service d'Hématologie, CHU Jean Minjoz
🇫🇷Besançon, France
Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine
🇫🇷Bordeaux, France
Centre Hospitalier Pierre Oudot
🇫🇷Bourgoin-Jallieu, France
Service Hématologie, Centre Hospitalier de Dunkerque
🇫🇷Dunkerque, France
CHD Vendée
🇫🇷La Roche-sur-Yon, France
Service des maladies du sang, Hôpital Claude Huriez, CHRU de Lille
🇫🇷Lille, France
Département d'Hématologie et Oncologie, Centre Léon Bérard
🇫🇷Lyon, France
Institut Universitaire du Cancer
🇫🇷Toulouse, France
Service Hématologie, UNIVERSITE DE ROUEN, CENTRE HENRI BECQUEREL
🇫🇷Rouen, France
Service Hématologie, Institut Curie - Hôpital René HUGUENIN
🇫🇷Saint-Cloud, France
Service Hématologie, Centre Hospitalier de Roubaix - Hôpital Victor Provo
🇫🇷Roubaix, France
Hôpitaux Universitaires de Strasbourg
🇫🇷Strasbourg, France
Unité d'Hématologie Clinique, CH D'ARRAS
🇫🇷Arras, France
Service d'Hématologie, Institut d'Hématologie de Basse Normandie
🇫🇷Caen, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Bénite, France
Service d'Hématologie et Thérapie Cellulaire, Centre Hospitalier Universitaire de Poitiers
🇫🇷Poitiers, France
Service Hématologie, CH YVES LE FOLL
🇫🇷Saint-Brieuc, France
Département d'Hématologie Clinique et Thérapie Cellulaire, Institut de Cancérologie Lucien Neuwirth
🇫🇷Saint-Priest-en-Jarez, France